1. Home
  2. TRUG vs QNTM Comparison

TRUG vs QNTM Comparison

Compare TRUG & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRUG
  • QNTM
  • Stock Information
  • Founded
  • TRUG 1983
  • QNTM 1998
  • Country
  • TRUG United States
  • QNTM Canada
  • Employees
  • TRUG N/A
  • QNTM N/A
  • Industry
  • TRUG
  • QNTM
  • Sector
  • TRUG
  • QNTM
  • Exchange
  • TRUG NYSE
  • QNTM NYSE
  • Market Cap
  • TRUG 8.4M
  • QNTM 35.6M
  • IPO Year
  • TRUG N/A
  • QNTM N/A
  • Fundamental
  • Price
  • TRUG $0.24
  • QNTM $13.46
  • Analyst Decision
  • TRUG Strong Buy
  • QNTM
  • Analyst Count
  • TRUG 1
  • QNTM 0
  • Target Price
  • TRUG $2.00
  • QNTM N/A
  • AVG Volume (30 Days)
  • TRUG 8.4M
  • QNTM 210.7K
  • Earning Date
  • TRUG 05-15-2025
  • QNTM 05-14-2025
  • Dividend Yield
  • TRUG N/A
  • QNTM N/A
  • EPS Growth
  • TRUG N/A
  • QNTM N/A
  • EPS
  • TRUG N/A
  • QNTM N/A
  • Revenue
  • TRUG $22,236,072.00
  • QNTM N/A
  • Revenue This Year
  • TRUG $24.05
  • QNTM N/A
  • Revenue Next Year
  • TRUG $31.65
  • QNTM N/A
  • P/E Ratio
  • TRUG N/A
  • QNTM N/A
  • Revenue Growth
  • TRUG 8.40
  • QNTM N/A
  • 52 Week Low
  • TRUG $0.17
  • QNTM $2.70
  • 52 Week High
  • TRUG $1.52
  • QNTM $23.81
  • Technical
  • Relative Strength Index (RSI)
  • TRUG 46.22
  • QNTM 73.02
  • Support Level
  • TRUG $0.20
  • QNTM $10.75
  • Resistance Level
  • TRUG $0.42
  • QNTM $13.44
  • Average True Range (ATR)
  • TRUG 0.05
  • QNTM 1.39
  • MACD
  • TRUG 0.00
  • QNTM 0.22
  • Stochastic Oscillator
  • TRUG 25.14
  • QNTM 83.46

About TRUG TRUGOLF HOLDINGS INC

TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games (including Links, a sports game for PC), hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.

About QNTM QUANTUM BIOPHARMA LTD

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

Share on Social Networks: